常山药业(300255.SZ)：拟吸收合并全资子公司梅山科技

Core Viewpoint - Changshan Pharmaceutical (300255.SZ) plans to optimize its asset allocation and reduce management costs by absorbing its wholly-owned subsidiary, Hebei Meishan Polysaccharide Peptide Technology Co., Ltd. (Meishan Technology) [1] Group 1 - The absorption merger will result in the legal cancellation of Meishan Technology [1] - All business operations, assets, debts, and other rights and obligations of Meishan Technology will be inherited by the company [1]